-2%
Amphoject is indicated for the following:
- Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
- Treatment of Cryptococcal Meningitis in HIV infected patients
- Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections refractory to Amphoject deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of Amphoject deoxycholate.
- Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Amphoject, relapse rates were high following initial clearance of parasites
Systemic Fungal Infections-
- Test dose: 1 mg IV infused over 20-30 min
- Load: 0.25-0.5 mg/kg IV infused over 2-6 hour
- Maintenance: 0.25-1 mg/kg IV qDay OR up to 1.5 mg/kg IV every other day (may increase gradually by 0.25 mg-increments/day)
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন‘
Interaction
Increased toxicity with flucytosine. Drug induced renal toxicity enhanced in presence of other nephrotoxic medications. Antagonises effects of azole antifungals.
Contraindications
Amphotericin B is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.
Side Effects
Common side effects are Fever, chills, convulsions, malaise; nausea, vomiting, diarrhoea, anorexia; tinnitus, vertigo, hearing loss; hypotension, hypertension, cardiac arrhythmias; peripheral neuropathy; phloebitis, pain at Inj site, disturbances in renal function and renal toxicity.
Pregnancy & Lactation
Pregnancy Category B. There have been no adequate and well-controlled studies of Amphotericin B in pregnant women. It is not known whether Amphotericin B is excreted in human milk.
Precautions & Warnings
As with any Amphoject-containing product the drug should be administered by medically trained personnel. During the initial dosing period, patients should be under close clinical observation. Amphoject has been shown to be significantly less toxic than Amphoject deoxycholate; however, adverse events may still occur.
Therapeutic Class
Other Antifungal preparations
Reconstitution
Aseptically add 12 mL of Sterile Water for Injection, to each Amphoject vial to yield a preparation containing 4 mg Amphoject/mL. Immediately after the addition of water, shake the vial vigorously for 30 seconds to completely disperse the Amphoject. This forms a yellow, translucent suspension. Visually inspect the vial for particulate matter and continue shaking until completely dispersed.
Storage Conditions
Unopened vials of lyophilized material are to be stored at temperatures up to 25°C. The reconstituted product concentrate may be stored for up to 24 hours at 2-8° C.